FDA Accepts ID Biomedical’s Fluviral For Accelerated Approval Pathway
This article was originally published in The Pink Sheet Daily
Executive Summary
Accelerated approval could allow the company to market the influenza vaccine in the U.S. in time for the 2006-2007 flu season, the company says. ID Biomedical previously discussed the possibility of launching in 2005.